Cancer research toward the integration of CAR-T therapy and microenvironment-targeted radionuclide therapy

2023 Fiscal Year Final Research Report

• Project/Area Number: 19H03606
• Research Category: Grant-in-Aid for Scientific Research (B)
• Allocation Type: Single-year Grants
• Section: 一般
• Review Section: Basic Section 52040:Radiological sciences-related
• Research Institution: Osaka Medical and Pharmaceutical University (2021-2023); Osaka University of Pharmaceutical Sciences (2019-2020)
• Principal Investigator: Temma Takashi 大阪医科薬科大学, 薬学部, 教授 (90378787)
• Co-Investigator(Kenkyū-buntansha): 近藤 直哉 大阪医科薬科大学, 薬学部, 助教 (80756172) ; 藤森 功 大阪医科薬科大学, 薬学部, 教授 (70425453) ; 秋澤 宏行 昭和薬科大学, 薬学部, 教授 (90311795) ; 尾江 悟 昭和薬科大学, 薬学部, 助教 (90756107) ; 平田 雅彦 大阪医科薬科大学, 薬学部, 講師 (00268301)
• Project Period (FY): 2019-04-01 – 2024-03-31
• Keywords: 放射性医薬品 / がん微小環境 / 内用放射線療法

Outline of Final Research Achievements

We have undertaken the development of radiotherapeutic agents targeting cancer-associated adipocytes (CAA) and tumor-associated macrophages (TAM) present around cancer cells to enable the application of CAR-T therapy to solid tumors, which has garnered attention in the field of cancer treatment. As specific target molecules, we selected adipocyte-type fatty acid-binding protein for CAA and matrix metalloproteinase-12, p38α, and signal transducer and activator of transcription 3 for TAM. We developed radioactive halogen-labeled probes based on small molecule compounds for all these targets. Although we did not achieve therapeutic efficacy, we succeeded in demonstrating their effectiveness as imaging probes.

Free Research Field

放射性薬品化学

Academic Significance and Societal Importance of the Research Achievements

本研究で開発したがん微小環境を標的とする新規プローブ群の内用放射線治療への展開が可能となれば、CAR-T治療だけでなくがん細胞を対象とする他の治療法との組み合わせにより、がん治療成績の向上が期待できる。また開発した新規プローブ群の核医学診断への展開が可能となれば、疾患の早期診断や適切な治療法選択への貢献も期待できる。